The global demand for Severe Combined Immunodeficiency Market is presumed to reach the market size of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% under the study period 2022 - 2028.
Severe combined immunodeficiency (SCID) refers to the rare genetic disorder caused by a mutation in genes which are involved in the development and function of immune cells which fights against infection. It is a type of primary immune deficiency and can cause life-threatening problems with the immune system. It is characterized by low to absent T cells and a low, high, or normal number of B cells and natural killer cells. Infants with SCID may appear healthy at birth but can be highly susceptible to severe infection. Its symptoms can involve failure to thrive, chronic diarrhoea, and frequent, often serious respiratory infections. Bone marrow transplant is the most common treatment for SCID.
Market Dynamics
The key factor driving the demand for severe combined immunodeficiency is the increasing demand for antibody infusion and bone marrow transplants for the treatment of children. The increase in awareness of the screening and diagnosis of these disorders is fostering the demand for this market. The availability of medications and immune-related treatments, along with the rising adoption of stem cell therapy and gene therapy, are boosting the demand for this market. Continuous advancement in technology and technological developments in screening techniques are expected to create lucrative growth opportunities for this market. Growing investment in research and development for the diagnosis and treatment, especially in gene therapy, is augmenting the demand for this market.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of severe combined immunodeficiency. The growth and trends of severe combined immunodeficiency industry provide a holistic approach to this study.
Market Segmentation
This section of the severe combined immunodeficiency market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Disease Type
- Ada-Scid
- X-Linked Scid
- Others
By Treatment
- Stem Cell Therapy
- Gene Therapy
- Enzyme Therapy
- Others
By End User
- Hospitals
- Ambulatory Surgical Centers
- Others
Regional Analysis
This section covers the regional outlook, which accentuates current and future demand for the Severe Combined Immunodeficiency market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Severe Combined Immunodeficiency Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the severe combined immunodeficiency market include Baxter International Inc., LFB S.A., Biotest AG, Shire Plc, Grifols S.A., Kedrion Biopharma Inc., Sanquin, CSL Behring, China Biologic Products Holdings Inc., and Octapharma AG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
